- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06890338
En undersøgelse til vurdering af anti-tumoraktivitet af intravenøst (IV) infunderet carboplatin med mirvetuximab soravtansin i deltagere med nyligt diagnosticeret folatreceptor alfa (FRa), der udtrykker serøs epitelcancer for avanceret trin, ovarie, ovarie, æggestokkene eller den primære peritoneale kræft.
En enkeltarm, fase 2-undersøgelse af neoadjuvant carboplatin og mirvetuximab soravtansin hos personer med frα-udtrykkende serøs ovarie-ovarie, æggestokk, ovarie, æggeledning eller primær peritoneal kræft
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC).
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States.
Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years .
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793
-
Mobile, Alabama, Forenede Stater, 36604
- Rekruttering
- Usa Mitchell Cancer Institute /ID# 276022
-
-
California
-
Irvine, California, Forenede Stater, 92618
- Rekruttering
- Kaiser Permanente - Irvine /ID# 276924
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- UCLA - University of California Los Angeles Medical Center /ID# 274566
-
San Diego, California, Forenede Stater, 92103
- Rekruttering
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891
-
San Francisco, California, Forenede Stater, 94109
- Rekruttering
- California Pacific Medical Center - Van Ness Campus /ID# 275329
-
Santa Barbara, California, Forenede Stater, 93105
- Aktiv, ikke rekrutterende
- Ridley Tree Cancer Center /ID# 275219
-
-
Connecticut
-
Danbury, Connecticut, Forenede Stater, 06810
- Rekruttering
- Danbury Hospital, Western Connecticut Health Network /ID# 274783
-
New Haven, Connecticut, Forenede Stater, 06510
- Rekruttering
- Yale University School of Medicine /ID# 275794
-
Norwalk, Connecticut, Forenede Stater, 06856
- Rekruttering
- Norwalk Hospital /ID# 274561
-
-
Florida
-
Jupiter, Florida, Forenede Stater, 33458
- Rekruttering
- Jupiter Medical Center /ID# 276616
-
Miami Beach, Florida, Forenede Stater, 33140
- Afsluttet
- Mount Sinai Medical Center /ID# 274868
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60607
- Rekruttering
- Rush Md Anderson Cancer Center /ID# 274926
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago Medical Center /ID# 274796
-
Peoria, Illinois, Forenede Stater, 61637-0001
- Rekruttering
- OSF St. Francis Medical Center /ID# 274752
-
Urbana, Illinois, Forenede Stater, 61801
- Rekruttering
- Carle Foundation Hospital /ID# 276470
-
-
Indiana
-
Fort Wayne, Indiana, Forenede Stater, 46845
- Rekruttering
- Parkview Research Center /ID# 274338
-
Indianapolis, Indiana, Forenede Stater, 46202
- Rekruttering
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40503
- Rekruttering
- Baptist Health Lexington /ID# 275218
-
Louisville, Kentucky, Forenede Stater, 40207
- Rekruttering
- Norton Cancer Institute - St. Matthews /ID# 276173
-
-
Louisiana
-
Covington, Louisiana, Forenede Stater, 70433
- Rekruttering
- Women'S Cancer Care /ID# 276469
-
New Orleans, Louisiana, Forenede Stater, 70112
- Rekruttering
- University Medical Center New Orleans /ID# 274755
-
Shreveport, Louisiana, Forenede Stater, 71103
- Rekruttering
- Willis-Knighton Medical Center /ID# 274310
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- Rekruttering
- University of Maryland, Baltimore /ID# 275308
-
Silver Spring, Maryland, Forenede Stater, 20910
- Rekruttering
- Holy Cross Hospital /ID# 275872
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455-0341
- Rekruttering
- University of Minnesota - Minneapolis /ID# 275718
-
Saint Louis Park, Minnesota, Forenede Stater, 55416
- Rekruttering
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- Rekruttering
- University Of Mississippi Medical Center /ID# 276342
-
-
Missouri
-
Springfield, Missouri, Forenede Stater, 65807
- Rekruttering
- Cox Medical Center South /ID# 274826
-
St Louis, Missouri, Forenede Stater, 63141
- Rekruttering
- Mercy David C. Pratt Cancer Center /ID# 275655
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89511
- Rekruttering
- The Center Of Hope /ID# 274313
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Rekruttering
- Dartmouth-Hitchcock Medical Center /ID# 274676
-
-
New Jersey
-
Hackensack, New Jersey, Forenede Stater, 07601
- Rekruttering
- John Theurer Cancer Center /ID# 275756
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Rutgers Cancer Institute of New Jersey /ID# 274358
-
Teaneck, New Jersey, Forenede Stater, 07666
- Rekruttering
- Holy Name Medical Center /ID# 276240
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87109
- Rekruttering
- Optimum Clinical Research Group /ID# 274583
-
-
New York
-
Bay Shore, New York, Forenede Stater, 11706
- Rekruttering
- Imbert Cancer Center /ID# 275634
-
Greenlawn, New York, Forenede Stater, 11740
- Rekruttering
- Northwell Health Cancer Institute At Huntington /ID# 276814
-
Lake Success, New York, Forenede Stater, 11042
- Rekruttering
- Northwell Health Center for Advanced Medicine. /ID# 275641
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Columbia University Irving Medical Center /ID# 276156
-
Rego Park, New York, Forenede Stater, 11374
- Rekruttering
- Northwell Health Queens Cancer Center /ID# 274850
-
West Islip, New York, Forenede Stater, 11795
- Rekruttering
- Good Samaritan Hospital Medical Center /ID# 274938
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- University of North Carolina Medical Center /ID# 275307
-
Charlotte, North Carolina, Forenede Stater, 28204
- Rekruttering
- Atrium Health Levine Cancer Institute /ID# 274557
-
Greenville, North Carolina, Forenede Stater, 27834
- Rekruttering
- East Carolina University - Brody School of Medicine /ID# 275770
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Rekruttering
- Atrium Health Wake Forest Baptist Medical Center /ID# 276952
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58102
- Rekruttering
- Sanford Fargo Medical Center - Fargo /ID# 275489
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinic - Cleveland /ID# 276133
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinic - Cleveland /ID# 278273
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinic - Cleveland /ID# 278274
-
Cleveland, Ohio, Forenede Stater, 44109
- Rekruttering
- Metrohealth Medical Center - Cleveland /ID# 276664
-
Columbus, Ohio, Forenede Stater, 43219
- Rekruttering
- The Mark H Zangmeister Center /ID# 275106
-
Kettering, Ohio, Forenede Stater, 45429
- Rekruttering
- Kettering Medical Center /ID# 274365
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Rekruttering
- Oncology Associates of Oregon, P.C. /ID# 275006
-
Tigard, Oregon, Forenede Stater, 97223
- Rekruttering
- Compass Oncology - West - Tigard /ID# 275101
-
Kontakt:
- Site Coordinator
- Telefonnummer: (971) 708-7600
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forenede Stater, 18015
- Rekruttering
- St. Lukes University Hospital /ID# 274362
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612
-
Pittsburgh, Pennsylvania, Forenede Stater, 15224
- Rekruttering
- West Penn Hospital /ID# 276028
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02905
- Rekruttering
- Women & Infants Hospital /ID# 274716
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Rekruttering
- Avera Cancer Institute - Sioux Falls /ID# 276226
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Rekruttering
- Sanford Cancer Center /ID# 274901
-
-
Texas
-
Austin, Texas, Forenede Stater, 78731
- Rekruttering
- Texas Oncology - Austin Central /ID# 275046
-
Fort Worth, Texas, Forenede Stater, 76104
- Rekruttering
- Texas Oncology - Fort Worth Cancer Center /ID# 275043
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Houston Methodist Hospital /ID# 274568
-
Kontakt:
- Site Coordinator
- Telefonnummer: 713.441.3250
-
San Antonio, Texas, Forenede Stater, 78240
- Rekruttering
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090
-
The Woodlands, Texas, Forenede Stater, 77380
- Rekruttering
- Texas Oncology - The Woodlands /ID# 275015
-
Tyler, Texas, Forenede Stater, 75702
- Rekruttering
- Texas Oncology - Northeast Texas /ID# 275057
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22903
- Rekruttering
- UVA Health University Hospital /ID# 275309
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456
-
Norfolk, Virginia, Forenede Stater, 23502-2800
- Rekruttering
- Virginia Oncology Associates- Norfolk (Brock) /ID# 275227
-
Roanoke, Virginia, Forenede Stater, 24014
- Rekruttering
- Carilion Roanoke Memorial Hospital /ID# 274684
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99204
- Rekruttering
- Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
- Rekruttering
- West Virginia University School of Medicine /ID# 274556
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
-
Be judged by the investigator and/or treating physician to be an appropriate candidate to receive neoadjuvant chemotherapy.
-
Diagnosis of biopsy-confirmed high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer.
-
Participant meets the following disease criteria:
- Stage III or IV disease by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging system, and
- Folate Receptor Alpha (FRα) expression positivity as defined by immunohistochemical staining of >= 75% of viable tumor cells with moderate >= 2+ membrane staining by the Ventana Folate Receptor Alpha (VENTANA FOLR1) assay, FOLR1 Eligibility Testing - Ventana FOLR1 (FOLR1-2.1) RxDx - Commercial or Central, and
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.
Exclusion Criteria:
-
Endometrioid, clear cell, mucinous, or sarcomatous tumor histology; mixed tumors containing any of the above histologies; or low-grade/borderline ovarian tumor.
-
Previous clinical diagnosis of noninfectious interstitial lung disease, including noninfectious pneumonitis.
-
Previously treated with anticancer therapy including chemotherapy, radiation therapy, immunotherapy, or biologic agent for current cancer, with the exception of one cycle of single agent carboplatin
-
Participants with the following ocular history and/or concurrent disorders:
- History of corneal transplantation;
- Undergoing active postoperative management for refractive surgery, cataract surgery, corneal cross-linking, or corneal complications of surgery;
- Confluent superficial punctate keratopathy (SPK) not expected to resolve to non-confluence or better within the screening window with standard of care (SOC) intervention;
- Active or chronic clinically significant (>= Grade 3) corneal dystrophy (e.g., Fuchs dystrophy);
- Active ocular conditions requiring ongoing treatment/monitoring, such as glaucoma, which is not adequately controlled with medication or surgery, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema or an ocular condition with high risk of retinal detachment;
- Monocular vision with visual acuity in the worse eye, worse than 20/200 or visual fields less than 20 degrees (i.e., functional blindness in at least one eye).
-
History of other malignancy within 3 years prior to signing study consent. -- Note: Participants with tumors with a negligible risk for metastasis or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Carboplatin + Mirvetuximab Soravtansine
Participants will receive carboplatin in combination with mirvetuximab soravtansine on Day 1 of a 21-day cycle per dose +/- Bevacizumab per investigator's discretion. |
Intravenous (IV) infusion
Andre navne:
Intravenous (IV) infusion Intravenous (IV) infusion (per investigator's discretion) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response (OR) by Independent Central Review (ICR)
Tidsramme: Up to Approximately 3 years
|
OR is defined as the best overall response of radiographic complete response (CR) or partial response (PR) as assessed by ICR using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including interval debulking surgery (IDS). |
Up to Approximately 3 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants with Adverse Events (AE)
Tidsramme: Up to Approximately 3 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to Approximately 3 years
|
|
Percentage of Participants with AEs leading to study drug discontinuation or dose modification
Tidsramme: Up to Approximately 3 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to Approximately 3 years
|
|
Objective Response (OR) by Investigator
Tidsramme: Up to Approximately 3 years
|
OR is defined as the best overall response of radiographic CR or PR as assessed by investigator using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including IDS. |
Up to Approximately 3 years
|
|
Disease Control by ICR
Tidsramme: Up to Approximately 3 years
|
Disease control defined as CR, PR, or stable disease (SD) as assessed by ICR per RECIST Version 1.1 prior to subsequent anticancer therapy including IDS. |
Up to Approximately 3 years
|
|
Disease control by Investigator
Tidsramme: Up to Approximately 3 years
|
Disease control defined as CR, PR, or stable disease (SD) as assessed by investigator per RECIST Version 1.1 prior to subsequent anticancer therapy including IDS. |
Up to Approximately 3 years
|
|
Percentage of Participants With CA-125 Confirmed Response Per Gynecologic Cancer Intergroup (GCIG) Criteria
Tidsramme: Up to Approximately 3 years
|
The GCIG CA-125 response was defined as at least 50% reduction in CA-125. |
Up to Approximately 3 years
|
|
Progression-Free Survival (PFS) by investigator
Tidsramme: Up to Approximately 3 years
|
PFS by investigator, defined as the time from the date of C1D1 until PD per RECIST v1.1 as assessed by investigator or death from any cause, whichever occurs first. |
Up to Approximately 3 years
|
|
Percentage of Participants that Underwent Interval debulking surgery (IDS)
Tidsramme: Up to Approximately 3 years
|
Percentage of participants that underwent IDS during the course of the study treatment |
Up to Approximately 3 years
|
|
Percentage of participants with complete tumor cytoreduction at IDS
Tidsramme: Up to Approximately 3 years
|
Complete tumor cytoreduction is defined as the absence of macroscopically visible residual disease at the end of the surgery |
Up to Approximately 3 years
|
|
Percentage of participants with Incomplete Tumor Cytoreduction at IDS
Tidsramme: Up to Approximately 3 years
|
Defined as macroscopically visible residual tumor (≤ 1 cm or > 1cm) at the end of surgery. |
Up to Approximately 3 years
|
|
Change from baseline in disease-related symptoms as measured by the NCCN-FACT Ovarian Symptom Index (NFOSI-18) disease symptom subscale - physical (DRS-P)
Tidsramme: Up to Approximately 3 years
|
The NFOSI-18 provides a total score that sums all 18 items, plus 2 multi-item scales that assess physical disease-related symptoms (DRS-P; 9 items) and general function/well-being (F/WB; 3 items). |
Up to Approximately 3 years
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Neoplasmer efter histologisk type
- Kønssygdomme, kvindelige
- Neoplasmer i endokrine kirtler
- Neoplasmer, kirtel og epitel
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Karcinom
- Æggeledersygdomme
- Ovariale neoplasmer
- Karcinom, ovarieepitel
- Æggelederneoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kemikalier
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Koordinationskomplekser
- Bevacizumab
- Carboplatin
- Mirvetuximab soravtansine
Andre undersøgelses-id-numre
- M25-231
- GOG-3115 (Anden identifikator: GOG)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD-delingsadgangskriterier
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .